Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 28490629)

  • 1. Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs.
    Sanders MA; Haynes B; Nangia-Makker P; Polin LA; Shekhar MP
    J Biol Chem; 2017 Jun; 292(25):10347-10363. PubMed ID: 28490629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
    Haynes B; Gajan A; Nangia-Makker P; Shekhar MP
    Biochim Biophys Acta Mol Basis Dis; 2020 Jan; 1866(1):165561. PubMed ID: 31639439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel inhibitors of Rad6 ubiquitin conjugating enzyme: design, synthesis, identification, and functional characterization.
    Sanders MA; Brahemi G; Nangia-Makker P; Balan V; Morelli M; Kothayer H; Westwell AD; Shekhar MPV
    Mol Cancer Ther; 2013 Apr; 12(4):373-83. PubMed ID: 23339190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nano-delivery of
    Saadat N; Liu F; Haynes B; Nangia-Makker P; Bao X; Li J; Polin LA; Gupta S; Mao G; Shekhar MP
    Mol Cancer Ther; 2018 Dec; 17(12):2586-2597. PubMed ID: 30242094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rad6/Rad18 Competes with DNA Polymerases η and δ for PCNA Encircling DNA.
    Li M; Larsen L; Hedglin M
    Biochemistry; 2020 Feb; 59(4):407-416. PubMed ID: 31887036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
    Haynes BM; Cunningham K; Shekhar MPV
    BMC Cancer; 2022 Oct; 22(1):1073. PubMed ID: 36258187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization.
    Haynes B; Zhang Y; Liu F; Li J; Petit S; Kothayer H; Bao X; Westwell AD; Mao G; Shekhar MPV
    Nanomedicine; 2016 Apr; 12(3):745-757. PubMed ID: 26563438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAD6B overexpression confers chemoresistance: RAD6 expression during cell cycle and its redistribution to chromatin during DNA damage-induced response.
    Lyakhovich A; Shekhar MP
    Oncogene; 2004 Apr; 23(17):3097-106. PubMed ID: 14981545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
    Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
    Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
    Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
    Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of platinum-DNA adduct repair.
    Chaney SG; Vaisman A
    J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of Rad6/Rad18 Activity During DNA Damage Tolerance.
    Hedglin M; Benkovic SJ
    Annu Rev Biophys; 2015; 44():207-28. PubMed ID: 26098514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance.
    Haynes B; Saadat N; Myung B; Shekhar MP
    Mutat Res Rev Mutat Res; 2015; 763():258-66. PubMed ID: 25795124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
    Raymond E; Buquet-Fagot C; Djelloul S; Mester J; Cvitkovic E; Allain P; Louvet C; Gespach C
    Anticancer Drugs; 1997 Oct; 8(9):876-85. PubMed ID: 9402315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and mechanistic studies of polymerase η bypass of phenanthriplatin DNA damage.
    Gregory MT; Park GY; Johnstone TC; Lee YS; Yang W; Lippard SJ
    Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9133-8. PubMed ID: 24927576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replication protein A dynamically regulates monoubiquitination of proliferating cell nuclear antigen.
    Hedglin M; Aitha M; Pedley A; Benkovic SJ
    J Biol Chem; 2019 Mar; 294(13):5157-5168. PubMed ID: 30700555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supramolecular complex formation between Rad6 and proteins of the p53 pathway during DNA damage-induced response.
    Lyakhovich A; Shekhar MP
    Mol Cell Biol; 2003 Apr; 23(7):2463-75. PubMed ID: 12640129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NBS1 recruits RAD18 via a RAD6-like domain and regulates Pol η-dependent translesion DNA synthesis.
    Yanagihara H; Kobayashi J; Tateishi S; Kato A; Matsuura S; Tauchi H; Yamada K; Takezawa J; Sugasawa K; Masutani C; Hanaoka F; Weemaes CM; Mori T; Zou L; Komatsu K
    Mol Cell; 2011 Sep; 43(5):788-97. PubMed ID: 21884979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.